BRCA Biomarkers
News and reporting on BRCA biomarkers.
858 Therapeutics Raises $50M in Series B Financing Round
Funds will be used to advance a Phase I trial of 858's PARG inhibitor ETX-19477 in advanced solid tumors.
Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined subset relative to all-comers.
Population Testing for BRCA1/2 Appears Cost-Effective in Younger Canadian Women
Using simulated data for 1 million women, researchers found that population-based BRCA1/2 testing would be cost-effective, particularly in 30-year-old women.
Researchers Aim to Confirm Benefits of Non-Hormonal Therapy for Certain Prostate Cancer Patients
Premium
Prostate cancer patients with BRCA2 and other homologous recombination repair mutations fared better on Lynparza than those without genomic alterations.
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.